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Articles

Global burden of acute lower respiratory infection associated
with human metapneumovirus in children under 5 years in
2018: a systematic review and modelling study
Xin Wang, You Li, Maria Deloria-Knoll, Shabir A Madhi, Cheryl Cohen, Asad Ali*, Sudha Basnet*, Quique Bassat*, W Abdullah Brooks*,
Malinee Chittaganpitch*, Marcela Echavarria*, Rodrigo A Fasce*, Doli Goswami*, Siddhivinayak Hirve*, Nusrat Homaira*, Stephen R C Howie*,
Karen L Kotloff*, Najwa Khuri-Bulos*, Anand Krishnan*, Marilla G Lucero*, Socorro Lupisan*, Ainara Mira-Iglesias*, David P Moore*,
Cinta Moraleda*, Marta Nunes*, Histoshi Oshitani*, Betty E Owor*, Fernando P Polack*, Katherine L O’Brien*, Zeba A Rasmussen*,
Barbara A Rath*, Vahid Salimi*, J Anthony G Scott*, Eric A F Simões*, Tor A Strand*, Donald M Thea*, Florette K Treurnicht*, Linda C Vaccari*,
Lay-Myint Yoshida*, Heather J Zar*, Harry Campbell, Harish Nair, for the Respiratory Virus Global Epidemiology Network†

Summary

Background Human metapneumovirus is a common virus associated with acute lower respiratory infections (ALRIs)
in children. No global burden estimates are available for ALRIs associated with human metapneumovirus in children,
and no licensed vaccines or drugs exist for human metapneumovirus infections. We aimed to estimate the agestratified human metapneumovirus-associated ALRI global incidence, hospital admissions, and mortality burden in
children younger than 5 years.
Methods We estimated the global burden of human metapneumovirus-associated ALRIs in children younger than
5 years from a systematic review of 119 studies published between Jan 1, 2001, and Dec 31, 2019, and a further 40 high
quality unpublished studies. We assessed risk of bias using a modified Newcastle-Ottawa Scale. We estimated
incidence, hospital admission rates, and in-hospital case-fatality ratios (hCFRs) of human metapneumovirusassociated ALRI using a generalised linear mixed model. We applied incidence and hospital admission rates of
human metapneumovirus–associated ALRI to population estimates to yield the morbidity burden estimates by age
bands and World Bank income levels. We also estimated human metapneumovirus-associated ALRI in-hospital
deaths and overall human metapneumovirus-associated ALRI deaths (both in-hospital and non-hospital deaths).
Additionally, we estimated human metapneumovirus-attributable ALRI cases, hospital admissions, and deaths by
combining human metapneumovirus-associated burden estimates and attributable fractions of human
metapneumovirus in laboratory-confirmed human metapneumovirus cases and deaths.
Findings In 2018, among children younger than 5 years globally, there were an estimated 14·2 million human
metapneumovirus-associated ALRI cases (uncertainty range [UR] 10·2 million to 20·1 million), 643 000 human
metapneumovirus-associated hospital admissions (UR 425 000 to 977 000), 7700 human metapneumovirus-associated
in-hospital deaths (2600 to 48 800), and 16 100 overall (hospital and community) human metapneumovirus-associated
ALRI deaths (5700 to 88 000). An estimated 11·1 million ALRI cases (UR 8·0 million to 15·7 million), 502 000 ALRI
hospital admissions (UR 332 000 to 762 000), and 11 300 ALRI deaths (4000 to 61 600) could be causally attributed to
human metapneumovirus in 2018. Around 58% of the hospital admissions were in infants under 12 months, and
64% of in-hospital deaths occurred in infants younger than 6 months, of which 79% occurred in low-income and
lower-middle-income countries.
Interpretation Infants younger than 1 year have disproportionately high risks of severe human metapneumovirus
infections across all World Bank income regions and all child mortality settings, similar to respiratory syncytial virus
and influenza virus. Infants younger than 6 months in low-income and lower-middle-income countries are at greater
risk of death from human metapneumovirus-associated ALRI than older children and those in upper-middle-income
and high-income countries. Our mortality estimates demonstrate the importance of intervention strategies for infants
across all settings, and warrant continued efforts to improve the outcome of human metapneumovirus-associated
ALRI among young infants in low-income and lower-middle-income countries.
Funding Bill & Melinda Gates Foundation.
Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license.

Introduction
Acute lower respiratory infections (ALRIs) are one of the
leading causes of morbidity and mortality in children
www.thelancet.com/lancetgh Vol 9 January 2021

globally, accounting for 10% of deaths in children younger
than 5 years in 2017.1 Human metapneumovirus, first
identified in 2001, is an important virus that causes ALRIs
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Research in context
Evidence before this study
Human metapneumovirus is a common virus in children with
acute lower respiratory infection (ALRI). Two pooled analyses
have shown that human metapneumoviruses are identified in
6·1–6·4% of ALRIs in patients younger than 20 years globally.
However, no global estimates of human metapneumovirusassociated ALRI burden are available for children younger than
5 years. The estimation of global human metapneumovirus
burden is challenging due to the paucity of population-based
studies on the incidence of human metapneumovirus infections.
Added value of this study
We did a meta-analysis based on published and unpublished
data on laboratory-confirmed human metapneumovirusassociated ALRI incidence, hospital admissions, and mortality
burden. We included 159 studies with data on human
metapneumovirus-associated ALRI community incidence,
hospital admission rates, proportion of human
metapneumovirus-positive cases among hospitalised ALRI
cases, and in-hospital case-fatality ratios, which included
40 high quality unpublished studies that provided data stratified
by narrow age groups in children younger than 5 years. 27% of
the studies were from low-income and lower-middle-income
countries. Our estimates of human metapneumovirusassociated ALRI burden were stratified by the level of child
mortality of the setting and by age groups, from which we
identified the population subgroups most susceptible to human
metapneumovirus-associated ALRI morbidity and mortality,
identifying target populations and settings for future
intervention studies and informing intervention strategies.
Since the presence of human metapneumovirus in the upper
respiratory tract in children with ALRIs does not indicate
causation, we reported the global burden of ALRIs that are
causally attributable to human metapneumovirus (human
metapneumovirus-attributable ALRI burden), which could aid
understanding with regard to the involvement of this virus in
causing childhood ALRI. We estimated that human

in young children.2–5 Previous evidence indicates that most
children are infected with human metapneumovirus
by age 5 years, with most severe infections occurring
in infants, including symptomatic and asymptomatic
infections.6–10 Pooled analyses have shown that human
metapneumovirus is associated with 6·1–6·4% of hospital
admissions due to ALRI among patients younger than
20 years worldwide.11,12 Few studies have reported the
incidence and mortality for human metapneumovirusassociated ALRIs, and studies have rarely reported disease
burden in narrower age groups (eg, those younger than
6 months). No global or regional burden estimates are
available for children under 5 years.
A live-attenuated recombinant human metapneumo
virus vaccine has been assessed in a phase 1 clinical
trial; however, study findings showed that the vaccine

metapneumovirus could be identified in 11% of ALRI cases,
4–13% of hospital admissions due to ALRIs, and 2% of ALRI
deaths among children under 5 years globally, using our
estimates in conjunction with previously published all-cause
ALRI burden estimates. After accounting for the causal
attribution of human metapneumovirus, we estimated that
8% of ALRI cases, 3–10% of hospital admissions due to ALRIs,
and 1% of ALRI-associated mortality could be attributed to
human metapneumovirus. About 58% of these hospital
admissions occurred in the first year of life. About 64% of the
in-hospital deaths occurred in infants younger than 6 months,
including 79% occurring in low-income and lower-middleincome countries.
Implications of all the available evidence
To our knowledge, our systematic review provides the first
estimates of global human metapneumovirus-associated
ALRIs and human metapneumovirus-attributable ALRI
morbidity and mortality in children under 5 years overall and
stratified by narrow age bands (0–5 months, 6–11 months,
and 12–59 months). Our results indicate that infants younger
than 1 year have an increased risk of severe human
metapneumovirus-associated ALRIs compared with older
children. Infants younger than 6 months, especially those in
low-income and lower-middle-income countries, are at
greater risk of death from human metapneumovirusassociated ALRIs than older infants and those from upper
middle-income countries and high-income countries. These
findings warrant continued efforts to develop targeted
intervention strategies to protect infants from human
metapneumovirus infections, and to improve the outcome of
infants with human metapneumovirus-associated ALRIs,
especially in low-income and lower-middle income countries.
Such strategies could include specific antiviral therapeutics,
monoclonal antibodies, or vaccination for children and their
mothers during pregnancy.

had insufficient immunogenicity in children aged
6–59 months.13 Antivirals against human metapneumo
virus infections and several other types of vaccines have
been investigated, but have not reached clinical trials.14–16
We aimed to estimate the global and regional number
of human metapneumovirus-associated ALRI cases,
hospital admissions, and mortality by age strata in
children under 5 years for 2018, using published and
unpublished data on laboratory-confirmed (culture,
immunofluorescence assay, or molecular test) human
metapneumovirus morbidity and mortality. Since the
presence of human metapneumovirus in the upper
respiratory tract in children does not indicate that
ALRI symptoms were directly caused by these viruses,
we also estimated the global burden of ALRI that is
attributable to human metapneumovirus by accounting
www.thelancet.com/lancetgh Vol 9 January 2021
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for the causal attribution of human metapneumovirus.
The estimates would provide evidence for the further
development of targeted interventions and treatment.

standardised approaches and definitions within the
collaborative Respiratory Virus Global Epidemiology
Network.19

Methods

Assessment of risk of biases

Systematic review
We did a systematic review of the human meta
pneumovirus-associated ALRI disease burden in children
under 5 years (appendix pp 4–5). We searched MEDLINE
(Ovid), Embase (Ovid), Global Health 1973 onwards
(Ovid), CINAHL, Web of Science, Global Health Library,
and three Chinese databases (CNKI, Wanfang, and
Chongqing VIP) for studies published between Jan 1, 2001,
and Dec 31, 2019. To search the grey literature, we did
broad searches through Google using the same date
restrictions and the search terms “acute respiratory
infections” AND “child” AND “parainfluenza virus”. No
language or publication restrictions were applied. Three
authors (XW, LCV, and YL) screened the titles and
abstracts for eligibility and extracted data independently.
Disagreements were resolved by discussion between the
authors.
We included studies that reported any of the following
data in children younger than 5 years: community inci
dence rates of ALRIs (ie, clinical pneumonia according
to 2005 WHO Integrated Management of Childhood
Illnesses17) with laboratory-confirmed human meta
pneumo
virus; rates of hospital admissions for ALRIs
(ie, physician-confirmed diagnosis of ALRI) or ALRIs
with hypoxaemia confirmed by pulse oximetry both
with laboratory-confirmed human metapneumo
virus
(per 1000 children per year); proportion of ALRIs with
laboratory-confirmed human metapneumovirus cases
among hospitalised ALRI cases; or in-hospital casefatality ratios (hCFRs) of ALRIs with laboratoryconfirmed human metapneumovirus. Case definitions
are included in the appendix (pp 2–3).18
Studies had to use clear case definitions for specimen
collection and testing, and studies that reported incidence
and hospital admission rate data had to include data for
at least one complete calendar year (or at least one full
season if in a temperate region). We included hCFR
data for any length of study period. We included data on
the proportion of human metapneumovirus-positive
cases among hospitalised ALRI cases if reported for at
least one full calendar year.
We excluded studies: without a clear denominator
population at risk (limited to those reporting incidence
and hospital admission rate data); those in which human
metapneumovirus was not the primary outcome; those
reporting modelled burden estimates; those in which
human metapneumovirus infections were diagnosed on
the basis of serology alone; and those only including
population subgroups with high-risk conditions.
We supplemented data from published studies with
high quality unpublished data (from ongoing studies or
re-analysis of previously published studies) using agreed
www.thelancet.com/lancetgh Vol 9 January 2021

We used a modified Newcastle-Ottawa Scale to assess the
risk of bias in seven domains, including study design,
adjustment for health utilisation, patient groups excluded,
definition, sampling strategy, diagnostic testing, and
hypoxaemia ascertainment (appendix pp 25–26).18,20

Statistical analysis
Our burden estimation approaches, including main
analyses and sensitivity analyses, are summarised in the
appendix (p 14). We estimated the number of human
metapneumovirus-associated ALRI cases, hospital admis
sions, and in-hospital deaths using a similar strategy to
our previous analysis.18 For the incidence rate and hospital
admission rate, we scaled the population-at-risk for the
level of testing per study where available before metaanalyses (appendix p 23). In a meta-analysis, we estimated
incidence rates, hospital admission rates, and hCFRs of
human metapneumovirus-associated ALRI using a
generalised linear mixed model.21
After meta-analyses, we estimated number of cases
and number of hospital admissions using Monte Carlo
simulation, which enabled the combination of metaestimates and population estimates (UN 2018 population
estimates).22 The median value of 10 000 samples
simulated from a log-normal distribution was used
as the point burden estimate and the 2∙5th and
97∙5th percentiles as the 95% uncertainty ranges (URs).
We used the same strategy as our previous studies, for
consistency; alternative methods (such as resampling
observed data) are likely to yield comparable estimates.23
In the main analysis, we reported estimates stratified
by three non-overlapping age groups (0–5 months,
6–11 months, and 12–59 months) and by child mortality
level of the setting from 2018 data (stratified into low or
high; using the median under-5 mortality rate [16·6 per
1000 livebirths] as the cutoff point) for each outcome
where available.24 Global results were calculated as the
sum of age-specific and region-specific estimates. The
numbers of cases were rounded to the nearest thousand,
and deaths were rounded to the nearest hundred. In
the community setting, we reported the incidence rate
for the overall age group (0–59 months) because data
were insufficient to allow disaggregation by narrower
age bands. To incorporate information from studies
with data for other age bands (eg, 0–11 months), we
imputed the numbers of cases for 0–59 months using a
multiple imputation approach as previously described
(appendix pp 21–22).18
We estimated human metapneumovirus-associated
ALRI in-hospital deaths by combining the estimates
of hospital admissions and hCFRs of human meta
pneumovirus-associated ALRIs.18,19 Similar to morbidity
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estimation, global estimates of mortality were calculated
as the sum of the estimates, stratified by the three age
groups and by child mortality settings.
Many child deaths from ALRIs occur outside of
hospitals, especially in resource-limited settings due to
low care-seeking or restricted access to care. Thus, we
estimated an inflation factor ratio of overall ALRI deaths
to in-hospital ALRI deaths at eight sites in six countries
with high child mortality (Mozambique, Kenya, South
Africa, Burkina Faso, and Ghana in sub-Saharan Africa,
and Bangladesh in south Asia).18,25–27 We calculated the
median inflation factor, which was extrapolated to other
countries with high child mortality, and we applied this
inflation factor to estimates of in-hospital deaths to
yield overall human metapneumovirus-associated ALRI
mortality (appendix p15).18,19,28 We assumed that human
metapneumovirus prevalence was the same in ALRI

5172 records identified through database search

200 records identified through other sources

1583 duplicates removed

3789 records screened

2565 records excluded as not relevant to topic

1224 full-text articles assessed for eligibility

1110 full-text articles excluded
590 no data for children aged 0–59 months
202 irrelevant to human metapneumovirus
204 no rate for full seasons or for complete
calendar years
81 duplicate data
4 no denominator
5 reported modelled estimates
3 in people with high-risk conditions
10 abstracts only
1 unable to translate (Arabic)

114 articles included (119 studies)

40 unpublished studies from the collaboration
network (mutually exclusive to the published
studies)

Studies with incidence rates

Studies with hospital admission
rates

11 human metapneumovirusassociated ALRI
4 human metapneumovirusassociated severe ALRI

39 human metapneumovirusassociated ALRI
14 human metapneumovirusassociated ALRI with
hypoxaemia

115 studies with data on
proportion of hospitalised
ALRI cases positive for
human metapneumovirus
and in-hospital case-fatality
ratios

Figure: Flow diagram for selection of studies on human metapneumovirus-associated ALRIs
ALRIs=acute lower respiratory infections.
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community deaths and in-hospital deaths. For settings
with low child mortality, the reciprocal of the proportion
of children with pneumonia symptoms who received
care, measured in Multiple Indicator Cluster Surveys,
Demographic and Health Surveys, and other national
surveys, was used as a proxy for the inflation factor.29
The inflation factor can be calculated for many countries
and regions, and it can thus help improve the estimates
of overall human metapneumovirus-associated ALRI
mortality. The median inflation factor for low child
mortality settings was extrapolated to other countries
with low child mortality without available data. Compared
with approximating the inflation factor using nonspecific ALRI mortality, in this approach we additionally
assumed that the case-fatality ratios for pneumonia in
hospitalised and non-hospitalised cases were broadly
similar.
The presence of human metapneumovirus in the
upper respiratory tract of a child with ALRI does not
indicate that human metapneumovirus caused the ALRI
symptoms in every instance. Thus, we estimated the ALRI
burden that is causally attributable to human meta
pneumovirus (ie, human metapneumovirus-attributable
ALRI burden) by combining the human meta
pneumovirus-associated ALRI burden estimates and the
proportion of laboratory-confirmed human meta
pneumovirus ALRI cases or deaths that are attributable to
human metapneumovirus (the attrib
utable fraction of
human metapneumovirus in human metapneumovirusassociated ALRI cases or deaths). We used a median value
of 78% as the input for the attributable fraction of
human meta
pneumovirus-associated ALRI cases based
on three multicountry studies.3–5 The attributable fraction
of human metapneumovirus-associated ALRI deaths was
calculated using the attributable fraction of human meta
pneumovirus-associated ALRI cases and the ratio between
hCFRs of human metapneumovirus-positive ALRIs and
human metapneumovirus-negative ALRIs. We assumed
that hCFR of human metapneumovirus-negative ALRIs
was equal to the hCFR of human metapneumoviruspositive ALRIs that were not deemed attributable to
human metapneumovirus (appendix p 17).
We
did
sensitivity
analyses
for
human
metapneumovirus-associated ALRI morbidity and inhospital deaths (appendix pp 9–13), and estimated burden
by country development status, according to UNICEF
definitions and World Bank income levels (low-income
and lower-middle-income, upper-middle-income, and
high-income).30,31 Additionally, we estimated the range
of human metapneumovirus-associated ALRI hospital
admissions by combining the proportion of hospitalised
ALRI cases positive for human metapneumovirus and
the 2015–16 estimates of all-cause ALRI hospital
admissions among children younger than 5 years.32,33
We also estimated overall human metapneumovirusassociated ALRI deaths for settings with high child
mortality by applying the proportion of human
www.thelancet.com/lancetgh Vol 9 January 2021
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metapneumovirus-positive deaths among all ALRI deaths
to the number of ALRI deaths in children under 5 years
for 2017.1 The proportion of human metapneumoviruspositive deaths among all ALRI deaths was estimated
using data from hospital-based studies included in the
systematic review.
As a final sensitivity analysis, we estimated human
metapneumovirus-attributable mortality for settings
with high child mortality by applying the proportion of
human metapneumovirus–attributable ALRI deaths to
the number of ALRI deaths in children under 5 years
from 2017.1 The proportion of human metapneumovirusattributable ALRI deaths was estimated using data
for December, 2016, to October, 2019, obtained from
Child Health and Mortality Prevention Surveillance
(appendix p 18).34 Details of included studies are in
the appendix (pp 34–53, 60–67). All analyses were
done in R (version 3.5.2).35 This study was done in
accordance with the Guidelines for Accurate and
Transparent Health Estimates Reporting recommen
dations (appendix p 59).36

Role of the funding source
The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. XW and HN had full access to all the data in
the study and HN had final responsibility for the decision
to submit for publication.
LMICs

Results
We identified 159 studies with data on human meta
pneumovirus-associated ALRI com
munity incidence,
hospital admission rates, the proportion of human
metapneumovirus-positive cases among hospitalised
ALRI cases, and hCFRs (figure); 119 studies were published
and 40 were unpublished studies from the Respiratory
Virus Global Epidemiology Network. Of the 159 studies
included, seven (4%) were from low-income countries,
36 (23%) from lower-middle-income countries, 67 (42%)
from upper-middle-income countries, and 49 (31%) from
high-income countries. The characteristics of the included
studies are summarised in the appendix (pp 6–7, 34–53).
11 studies reported the incidence of human
metapneumovirus-associated ALRIs (ie, ALRI cases with
laboratory confirmation of human metapneumovirus).
Ten studies provided data for the 0–59-month age group
after imputation, including six studies from settings
with high child mortality; five studies were from lowermiddle-income countries, two studies from uppermiddle-income countries, and three studies from
high-income countries (table 1). Four studies reported
incidence before 2010. Between 1990 and 2015, the mean
human metapneumovirus-associated ALRI incidence
meta-estimate was 22·1 per 1000 children per year
(95% CI 17·0–28·7) in children aged 0–59 months in
settings with high child mortality, and 18·9 (11·2–31·9)
in settings with low child mortality. The high incidence

UMICs

HICs

Settings with low
child mortality

For more on Child Health and
Mortality Prevention
Surveillance see
https://champshealth.org/

Settings with high
child mortality

0–5 months
Studies, n
Incidence (per 1000 children per year)*
Episodes (thousands)

5
30·2 (7·8–109·8)
1337 (359–4983)

1

0

0

NA

NA

NA

NA

NA

NA

6
35·4 (12·0–99·3)
1629 (570–4662)

6–11 months
Studies, n
Incidence (per 1000 children per year)*
Episodes (thousands)

5
30·7 (12·2–75·1)
1347 (546–3327)

1

0

0

NA

NA

NA

NA

NA

NA

6
32·8 (16·0–65·9)
1496 (740–3026)

12–59 months
Studies, n
Incidence (per 1000 children per year)*
Episodes (thousands)

4
23·1 (16·7–31·9)

1

0

0

NA

NA

NA

7923 (5743–10 933) NA

NA

NA

5
21·0 (15·4–28·6)
7490 (5506–10 192)

0–59 months†
Studies, n‡
Incidence (per 1000 children per year)*
Episodes (thousands)

5 (1)
21·3 (15·5–29·3)
9202 (6711–12 620)

2 (1)
16·5 (8·3–32·8)
3019 (1521–5996)

3 (2)
22·6 (13·4–38·2)
1436 (854–2415)

4 (3)
18·9 (11·2–31·9)
4347 (2588–7304)§

6 (1)
22·1 (17·0–28·7)
9891 (7620–12 842)§

Data in parentheses are estimated uncertainty ranges. Data were imputed using a multiple imputation approach. Meta-analyses were only done when two or more studies
were available. Settings in which the under-5 mortality rate was higher than the median under-5 mortality rate for 2018, were considered high child mortality settings, and
settings in which the under-5 mortality rate was lower than the median under-5 mortality rate for 2018, were considered low child mortality settings. LMICs=lower-middle
income countries. UMICs=upper middle-income countries. HICs=high-income countries. NA=not available. *Derived from meta-analysis. †Estimates were calculated by
applying rates for children aged 0–59 months to the population estimates. ‡Data in parentheses are the number of imputed studies. §Global number of human
metapneumovirus-associated acute lower respiratory infections cases in children aged 0–59 months was 14·2 million (uncertainty range 10·2 million to 20·1 million), which
was calculated by adding estimates from the two child mortality setting groups.

Table 1: Estimates of the incidence (per 1000 children per year) and number of human metapneumovirus-associated acute lower respiratory infection
cases in children younger than 5 years in the community in 2018, by age group, and by World Bank income level and level of child mortality by setting
(low vs high)
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LMICs

UMICs

HICs

Settings with
low child
mortality

Settings with
high child
mortality

Global
estimates*

Human metapneumovirus-associated ALRIs
0–5 months
Studies, n

8

6

5

7

Hospital admission rate (per
1000 children per year)†

2·4 (1·6–3·5)

3·3 (1·6–7·1)

3·3 (2·2–5·1)

2·7 (1·8–4)

Hospital admissions (thousands)

106 (72–157)

61 (29–128)

21 (14–32)

12

62 (42–93)

3·0 (1·9–4·9)
138 (86–221)

··
··
200 (128–314)

6–11 months
Studies, n

7

5

4

5

Hospital admission rate (per
1000 children per year)†

2·7 (1·7–4·3)

2·5 (1–5·9)

2·8 (2·2–3·5)

2·2 (1·5–3·4)

Hospital admissions (thousands)

119 (75–188)

46 (19–111)

18 (14–22)

11

51 (34–76)

2·7 (1·7–4·4)
123 (77–198)

··
··
174 (110–274)

12–59 months
Studies, n

9

8

5

7

Hospital admission rate (per
1000 children per year)†

0·6 (0·3–1)

0·4 (0·2–0·8)

0·3 (0·2–0·7)

0·3 (0·2–0·5)

Hospital admissions (thousands)

15
0·6 (0·4–0·8)

··
··

206 (113–375)

59 (29–117)

15 (8–28)

55 (35–87)

214 (152–302)

269 (187–389)

431 (260–720)

165 (77–356)

54 (36–83)

168 (110–255)

475 (315–721)

643 (425–977)

0–59 months‡
Hospital admissions (thousands)

Human metapneumovirus-associated ALRIs with hypoxaemia
0–5 months
Studies, n

6

3

Hospital admission rate (per
1000 children per year)†

0·3 (0–2·1)

1·3 (0·3–5·4)

Hospital admissions (thousands)

13 (1–268)

24 (6–101)

1
NA
NA

2

8

··

0·6 (0·2–1·5)

0·7 (0·2–2·5)

··

14 (5–38)

32 (9–113)

46 (14–151)

6–11 months
Studies, n

6

3

2

8

··

Hospital admission rate (per
1000 children per year)†

0·4 (0·1–2)

0·3 (0·1–1·2)

NA

0·3 (0·1–1·7)

0·5 (0·2–1·7)

··

6 (2–19)

NA

7 (2–28)

Hospital admissions (thousands)

18 (4–78)

1

23 (8–66)

30 (10–94)

12–59 months
Studies, n

6

4

Hospital admission rate (per
1000 children per year)†

0·1 (0–0·2)

0·1 (0–0·7)

Hospital admissions (thousands)

3

8

··

NA

1

0 (0–0·1)

0·1 (0–0·3)

··

34 (5–215)

15 (1–171)

NA

1 (0–4)

36 (5–273)

37 (5–277)

65 (10–560)

44 (9–291)

NA

22 (7–70)

91 (22–452)

112 (29–522)

0–59 months‡
Hospital admissions (thousands)

Data in parentheses are estimated uncertainty ranges. Meta-analyses were only done when at least two studies were available. Settings in which the under-5 mortality rate
was higher than the median under-5 mortality rate for 2018, were considered high child mortality settings, and settings in which the under-5 mortality rate was lower than
the median under-5 mortality rate for 2018, were considered low child mortality settings. ALRI=acute lower respiratory tract infection. LMICs=lower-middle-income
countries. UMICs=upper-middle-income countries. HICs=high-income countries. NA=not available. *Global estimates by age strata are the sum of estimates by child
mortality settings; global estimates for 0–59 months are the sum of estimates by age groups and child mortality settings. †Derived from the meta-analysis. ‡Estimates are
the sum of estimates for all three age groups (0–5 months, 6–11 months, and 12–59 months).

Table 2: Hospital admission rates (per 1000 children per year) and hospital admissions of human metapneumovirus-associated ALRI in children younger
than 5 years in 2018, by age group and by World Bank income levels and level of child mortality by setting (low vs high)

observed in settings with low child mortality was mainly
driven by two Australian studies (done between 1996 and
1999 and between 2010 and 2014).37,38 Using these metaestimates, we estimated that there were 14·2 million
human metapneumovirus-associated ALRI cases
(UR 10·2 million to 20·1 million) globally in children
younger than 5 years.
We identified 39 studies reporting human meta
pneumovirus-associated ALRI hospital admission rates,
e38

including 29 studies reporting data by three narrow age
groups (0–5 months, 6–11 months, or 12–59 months;
table 2). The hospital admission rate meta-estimate was
more than four times higher in infants aged 0–5 months
and 6–11 months (2·2–3·3 admissions per 1000 children
per year) than children aged 12–59 months (0·3–0·6
admissions per 1000 children per year) when stratified
by World Bank income levels and child mortality settings.
In the analysis stratified by child mortality settings,
www.thelancet.com/lancetgh Vol 9 January 2021
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LMICs
Studies, n

UMICs

15

6

HICs

Settings with low
child mortality

7

7

Settings with high
child mortality
21

Global estimates*
··

0–5 months
hCFR, %†

4·5% (2·3–8·6)

Deaths, n

4300 (2000–9200)

1·7% (0·6–5·1)
1000 (300–3700)

0·4% (0–8·6)
100 (0–3400)

0·4% (0–8·6)
200 (0–9900)

3·3% (1·7–6·1)
4600 (2100–9900)

··
4900 (2100–19 300)

6–11 months
hCFR, %†

0·7% (0–9)

NA

Deaths, n

900 (0–37 800)

NA‡

0·6% (0·1–3·9)
100 (0–700)

0·6% (0·1–3·9)
300 (0–1900)

0·2% (0–7·6)
200 (0–9400)

··
600 (100–11 300)

12–59 months
hCFR, %†
Deaths, n

0·9% (0·3–2·8)
1800 (500–6500)

1·1% (0·1–9·1)

0·5% (0–7·0)

0·5% (0–7)

0·9% (0·2–3·6)

··

600 (100–6600)

100 (0–2800)

300 (0–10 100)

1900 (400–8300)

2200 (400–18 300)

1700 (300–10 300)

300 (0–6900)

800 (100–22 200)

6800 (2500–27 100)

7700 (2600–48 800)

0–59 months§
Deaths, n

7200 (2600–52 300)

Data in parentheses are estimated uncertainty ranges. Settings in which the under-5 mortality rate was higher than the median under-5 mortality rate for 2018, were
considered high child mortality settings, and settings in which the under-5 mortality rate was lower than the median under-5 mortality rate for 2018, were considered low
child mortality settings. hCFR=in-hospital case-fatality ratio. ALRI=acute lower respiratory tract infection. LMICs=lower-middle-income countries. UMICs=upper middleincome countries. HICs=high-income countries. NA=not available. *Global estimates by age strata are the sum of estimates by child mortality settings; global estimates for
children aged 0–59 months are the sum of estimates by age and child mortality settings. †Estimates derived from the meta–analysis. ‡No human metapneumovirusassociated ALRI deaths were reported in any of the studies from upper middle-income countries; thus hCFR for the strata was not estimated. §Estimates for the 0–59 month
age group are the sum of estimates for the three age groups (0–5 months, 6–11 months, and 12–59 months).

Table 3: hCFR meta-estimates of human metapneumovirus-associated ALRI and in-hospital deaths in children younger than 5 years in 2018, by age
group and by World Bank income levels and level of child mortality by setting (low vs high)

we estimated that there were 643 000 human meta
pneumovirus-associated ALRI hospital admissions (UR
425 000–977 000) globally in children younger than 5 years
in 2018, of which 374 000 (58%) occurred in infants.
14 studies included hospital admission rates for human
metapneumovirus-associated ALRIs with hypoxaemia by
three age groups, including five studies from settings
with low child mortality (table 2). In the analysis stratified
by child mortality settings, we estimated that, globally,
112 000 (UR 29 000–522 000) hospital admissions were
for human metapneumovirus-associated ALRIs with
hypoxaemia in children aged 0–59 months in 2018,
accounting for 17% (ie, 112 000 of 643 000 cases) of the
human metapneumovirus-associated ALRI hospital
admissions.
73 studies reported hCFRs for human meta
pneumovirus-associated ALRI in children younger than
5 years, including 28 studies with data stratified by three
narrow age bands (table 3). hCFRs were highest in
infants aged 0–5 months from settings with high child
mortality (3·3%, 95% CI 1·7–6·1) and from lowermiddle-income countries (4·5%, 2·3–8·6). hCFRs were
lower in children from high-income countries who were
aged 6–11 months (0·6%, 0·1–3·9) and 12–59 months
(0·5%, 0–7·0) than infants aged 0–5 months from high
child mortality settings and from lower-middle-income
countries, with the estimates in older children having
notably wide confidence intervals. On the basis of these
meta-estimates, we estimated that there were 7700 human
metapneumovirus-associated ALRI in-hospital deaths
(UR 2600–48 800) in children younger than 5 years in
2018, of which 5500 (71%) occurred in infants. About
www.thelancet.com/lancetgh Vol 9 January 2021

64% of these deaths were in young infants aged
0–5 months (4900 deaths of 7700 total in-hospital
deaths), and 88% (6800 deaths of 7700 total in-hospital
deaths) occurred in countries with high child mortality.
Across 28 countries or regions with low child mortality,
22–94% of children with pneumonia received care from a
health provider (appendix p 16). About 71% of the data
were for the period 2010–14. On the basis of these data, we
estimated the median inflation factor was 1∙3 across
regions or countries, and thus that there were about
1100 human metapneumovirus-associated ALRI deaths
(UR 100–28 800; after rounding in-hospital deaths), in
hospitals and in the community, among children younger
than 5 years in settings with low child mortality in 2018.
Of the eight sites with data on pneumonia mortality in
high child mortality settings, five sites were in rural areas,
and six sites were in African countries. Six studies reported
data between 2010 and 2016, and the remaining two
studies reported data from 2008 onwards. The inflation
factor ranged from 1∙5 to 3∙5 across the eight sites,
with a median value of 2∙2 (IQR 1·7–2·7). Thus, we esti
mated that there were 14 900 human metapneumovirusassociated ALRI deaths (UR 5600–59 700; after rounding
in-hospital deaths), in hospitals and in the community, in
settings with high child mortality. We therefore estimate
that there were 16 100 human metapneumovirusassociated ALRI deaths (5700–88 000; ie, ALRI deaths in
children with laboratory-confirmed human metapneumo
virus) among children globally in 2018.
By applying the attributable fraction of human meta
pneumovirus to the estimated human metapneumovirusassociated burden, we estimated that 11·1 million ALRI
e39
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Attributable
fraction, %*

Human metapneumovirus-attributable ALRI cases (millions)

78%‡

Human metapneumovirus-attributable ALRI hospital admissions (thousands)

78%

Human metapneumovirus-attributable ALRI deaths

70%§

Global human
metapneumovirusassociated burden
estimates
14·2 (10·2–20·1)
643 (425–977)
16 100 (5700–88 000)

Global human
metapneumovirusattributable burden
estimates†
11·1 (8·0–15·7)
502 (332–762)
11 300 (UR 4000–61 600)

Data in parentheses are uncertainty ranges. ALRI=acute lower respiratory tract infection. *The proportion of human metapneumovirus-positive cases and deaths attributable
to human metapneumovirus. †Applying the corresponding attributable fraction to the estimates of human metapneumovirus-associated burden. ‡The attributable fraction
for human metapneumovirus-associated ALRI cases was calculated using odds ratios from a systematic review and two multi-country studies; the median odds ratio from
the three studies was input to yield the attributable fraction for human metapneumovirus-ALRI cases (78%); all references are in the appendix (p 18). §The attributable
fraction for human metapneumovirus-associated ALRI deaths was modelled using the attributable fraction for human metapneumovirus cases and the ratio of case-fatality
between human metapneumovirus-attributable cases and human metapneumovirus-associated cases (appendix pp 17–18).

Table 4: Estimates of global human metapneumovirus-attributable ALRI cases, hospital admissions, and mortality, projected using attributable fractions
that were calculated by use of inflation factors

cases (UR 8·0 million to 15·7 million) and 502 000 ALRI
hospital admissions (UR 332 000–762 000) could be
attributed to human metapneumovirus in children under
5 years (table 4). We estimated that the ratio of in-hospital
case fatalities of human metapneumovirus-attributable
ALRIs to human metapneumovirus-associated cases was
0·9 (appendix p 18), and the attributable fraction for
human metapneumovirus-associated ALRI deaths was
70% (appendix pp 17–18), indicating that 11 300 ALRI
deaths (UR 4000–61 600) globally could be attributed to
human metapneumovirus in 2018, including 10 400 deaths
(3900–41 800) in settings with high child mortality (table 4).
We did several sensitivity analyses to estimate
hospital admissions, in-hospital deaths, and overall human
metapneumovirus-associated ALRI deaths, and of human
metapneumovirus-attributable ALRI deaths (by country
development strata and World Bank income level) using
different approaches (appendix pp 8–13,16,19). For global
human meta
pneumovirus-associated ALRI hospital
admissions, the estimates in children younger than 5 years
ranged from 626 000 to 650 000 in analyses by different
stratification groups (appendix p 9); the proportion-based
approach yielded a broader range (282 000–902 000;
appendix p 10). The point estimate of global in-hospital
deaths ranged from 7200 to 9100 in children younger than
5 years, and an estimated 79% of the global in-hospital
deaths occurred in low-income and lower-middle-income
countries (7200 of 9100 deaths) when stratified by World
Bank income level (appendix p 11). We estimated
19 900 human metapneumovirus-associated ALRI deaths
(UR 12 100–33 200) and 9900 human metapneumovirusattributable ALRI deaths (UR 2600–39 300) in children
aged 1–59 months in settings with high child mortality
using a different approach (appendix pp 16, 19).

Discussion
To our knowledge, this is the first study to report global
human metapneumovirus-associated ALRI burden
estimates both among children younger than 5 years
overall and stratified by narrow age groups (0–5 months,
6–11 months, and 12–59 months). When compared with
e40

our previously published all-cause ALRI burden
estimates, human metapneumovirus is identified in
11% of ALRI cases, 4–13% of ALRI hospital admissions,
and 2% of ALRI deaths among children under 5 years
globally.1,32,33 About 8% of ALRI cases, 3–10% of ALRI
hospital admissions, and 1% of ALRI mortality can be
attributed to human metapneumovirus. The wide URs
of these burden estimates reflect differences across
studies, arising from variation in human metapneumo
virus epidemiology between populations and methodo
logical differences, and from paucity of data, especially
mortality data.
Similar to respiratory syncytial virus and influenza, we
found that the human metapneumovirus-associated
ALRI hospital admission rate was much higher in
infants than older children, with about 58% of hospital
admissions and 71% of in-hospital deaths due to human
metapneumovirus-associated ALRIs in children under
5 years occurring in the first year of life.18,19 The high
burden in infants could be due to the immaturity
of infants’ immune systems and decaying maternal
antibodies during the first several months of life.39,40 The
consistently high human metapneumovirus-associated
ALRI hospital admission rate among infants across
different settings highlights the importance of developing
safe and effective maternal human metapneumovirus
vaccines, particularly for infants.
Our hCFR estimates show that young infants aged
0–5 months are at an increased risk of human
metapneumovirus–associated ALRI mortality compared
with infants older than 5 months. hCFR estimates for
infants aged 0–5 months varied sub
stantially across
settings, possibly reflecting the differences in disease
severity at admission and in the quality of hospital care.
Increased disease severity at presentation could be
associated with the high prevalence of certain underlying
conditions and delays in care-seeking.3,33 The case-fatality
ratio (overall and in-hospital) and overall mortality due to
ALRI among children under 5 years has substantially
reduced in the past 15 years due to socioeconomic
development, reduced prevalence of pneumonia risk
www.thelancet.com/lancetgh Vol 9 January 2021
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factors, and increased use of interventions.33,41 However,
most studies spanning several years reported one to three
deaths from human metapneumovirus-associated ALRIs,
and we were unable to identify any changes in the hCFR of
human metapneumovirus-associated ALRI over time.
When stratifying the data using 2010 as a cutoff and using
available age-stratified data from studies done before 2010
(eligible if part of a study was done before 2010 and data
could not be stratified by year), we estimated that there
were 9600 human metapneumovirus-associated ALRI inhospital deaths (UR 2300–51 200) among children under
5 years in 2010 (appendix p 12).
For settings with high child mortality, the inflation
factor was based on scarce data.19 The estimates could be
biased due to limited generalisability and location-specific
characteristics (ie, prevalence of human metapneumovirus
in childhood ALRI deaths). However, our reported esti
mates of overall human metapneumovirus-associated
ALRI deaths for settings with high child mortality are
conservative and could increase by approximately 30%
(19 900 deaths) using an alternative estimation approach
(appendix p 16). For settings with low child mortality, the
inflation factor and overall mortality estimate are likely to
be underestimated because the definition of care-seeking
is broader than the definition of in-hospital care: contact
with primary care is included as care-seeking in surveys,
but not included in the in-hospital mortality estimates in
the present analysis. The US vital statistics data showed
that about 40% of under-5 ALRI deaths (International
Classification of Diseases, 10th revision diagnostic codes
J09–22; U04) occurred in outpatient or emergency
departments between 2010 and 2017.42 Additionally, this
analysis was based on one further assumption that no
differences exist between the case-fatality ratio for
hospitalised and non-hospitalised pneumonia cases. The
direction of bias associated with this assumption could be
complicated by the two-way association between disease
severity and care-seeking: children with more severe
symptoms are more likely to receive hospital care; whereas,
supportive care in hospitals can reduce the risk of death,
and lack of appropriate care or delays in care can lead to
rapid deterioration.43–45 Moreover, data on pneumonia careseeking in high-income countries were not available in
published reports; extrapolation from other countries with
low child mortality to high-income countries might result
in bias. The estimates of inflation factor could also be
affected by accuracy of assessment and completeness of
documentation for ALRI or pneumonia. For example, the
diagnosis of (presumptive) pneumonia in the UNICEF
dataset is based on caregivers’ report, thus might be
inaccurate and affect the estimates of inflation factor.
Our study had several other limitations. Little data were
available for Europe and Latin America, which could have
affected the generalisation of the estimates. Moreover,
heterogeneity in the methodology (ie, variations in precise
case definitions, proportion of eligible ALRI cases tested
for human metapneumovirus) existed across studies for
www.thelancet.com/lancetgh Vol 9 January 2021

each outcome and is likely to have biased our estimates
(appendix p 7). We adjusted for levels of testing when
estimating hospital admission rates by assuming that the
proportion of tested patients with ALRIs who were positive
for human metapneumovirus was the same as the
proportion in untested patients with ALRIs. However,
we did not adjust for the underdetection of human
metapneumovirus when estimating hCFRs. The hCFR
of human metapneumovirus-associated ALRIs and inhospital mortality might be underestimated, as suggested
by the higher hCFR in patients tested than untested
patients (appendix p 24). The incidence and hospital
admission rates of human metapneumovirus-associated
ALRI are unlikely to be affected by the accuracy of test
methods since 92% of the studies used PCR to detect
human metapneumovirus. In addition to potential biases,
we summed yearly data to ensure precision in the agestratified analysis; however, we did not account for
variation across years (appendix p 20).
Our results show that infants younger than 1 year
have disproportionately high risks of severe human
metapneumovirus infections across settings. Infants
aged 0–5 months in low-income and lower-middleincome countries have an increased risk of mortality
from human metapneumovirus-associated ALRIs com
pared with those in upper-middle-income countries and
high-income countries, accounting for nearly eight of
every ten global deaths occurring in this age group.
These estimates highlight the importance of inter
ventions for infants. In low-income and lower-middleincome countries, continued efforts are needed to reduce
human metapneumovirus-associated ALRI mortality
among young children, especially infants, in hospitals
and communities through improving access to care and
case management in hospitals. Considering the paucity
of data at the regional level, these estimates should be
viewed as preliminary estimates. In the future, additional
high quality data on childhood human metapneumovirusassociated ALRI cases, hospital admissions, and mortality,
especially age-stratified data, would help refine the
estimates and track changes in human metapneumovirusassociated ALRI morbidity and mortality over time.
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